Subscribe to RSS
DOI: 10.1055/s-0042-1750697
Periprosthetic Infections in Total Knee Arthroplasty: What Is Our Reality?
Article in several languages: español | EnglishAbstract
Introduction Periprosthetic infection (PPI) is one of the most serious complications in total knee arthroplasty (TKA). Despite this, there is little Chilean literature regarding this pathology.
Objectives To determine the incidence, comorbidities, isolated microorganisms and their antibiotic susceptibility, morbidity, and mortality in patients with PPI.
Materials and Methods A descriptive and retrospective study in patients operated between 2001 and 2020 for gonarthrosis, with a primary TKA, in the same health center, with at least 1 year of follow-up. Patients operated on in other centers or with incomplete clinical records were excluded. Comorbidities, isolated microorganisms, antibiotic susceptibility, and survival were recorded through a systematic search of the clinical records of patients with PPI. Descriptive statistics were used to present the data.
Results We included 544 TKAs, 8 (1.47%) of which presented PPI, and the patients had an average age at presentation of 66 years (±5.7 years) and an average body mass index (BMI) of 30.3 (±4, 5) kg/m2. The median time of presentation of the PPI was of 411 (±1,034) days. The main comorbidities recorded were arterial hypertension in 5 (62.5%), smoking in 4 (50%) cases, and dyslipidemia in 4 (50%) cases. In total, 5 (62.5%) patients presented polymicrobial etiology, and in 3 (37.5%), a single microorganism was isolated. The main isolated agents were Staphylococcus aureus and coagulase-negative Staphylococcus, both multidrug-resistant, in 6 (75%) and 3 (37.5%) patients respectively. All patients received three doses of cefazolin as surgical prophylaxis. A sensitivity of 100% to vancomycin and rifampicin (12/12 cultures), and a resistance of 83.4% to ciprofloxacin (4/9 cultures) were described. Overall, 2 (25%) patients died 3 years after the TKA, due to causes unrelated to PPI. There were no cases of infectious relapse after the review.
Conclusion An incidence of 1.47% (8 cases) of PPI was found. All patients with PPI presented some presurgical comorbidity. The main microbiological agents identified were multidrug-resistant and susceptible to vancomycin and rifampicin.
#
Introduction
Periprosthetic infection (PPI) is one of the most serious complications in total knee arthroplasty (TKA), with an incidence of around 0.29% in the United States and 2% in Spain.[1] [2] It is significantly associated with high morbidity and mortality, in addition to greater economic expenses and the need for surgical reintervention, with an estimated price of 6,815.4 dollars for each revision arthroplasty.[3] The main current advances are focused on the prevention, early diagnosis and treatment of PPIs, in order to reduce the rate and improve patient outcomes.[4]
Among the main risk factors related to PPIs, those linked to the patient's lifestyle stand out, such as obesity, excessive alcohol intake, active smoking, and the use of intravenous drugs. Factors related to comorbidities, such as diabetes, psoriasis, rheumatoid arthritis, and ankylosing spondylitis, are also relevant. On the other hand, there are risks associated with surgery, such as a surgical time longer than 90 minutes.[2] [5] [6]
The strategies for the prevention of PPIs are mainly preoperative antibiotic prophylaxis, preoperative skin cleaning, and the use of cemented prostheses loaded with antibiotics.[7]
Based on the current evidence, many centers continue to recommend the use of antibiotic prophylaxis with first- or second-generation cephalosporin, intravenously, during the preoperative period and in the following 24 hours after arthroplasty.[8]
The diagnosis of PPI remains a challenge due to multiple factors such as: false negative cultures, non-diagnostic laboratory tests, and heterogeneous clinical presentations.[9] [10] [11] In search of a more conclusive diagnostic tool, different classifications have been proposed, such as those by Tsukayama et al.[12] in 1996 or by the Musculoskeletal Infection Society (MSIS)[13] in 2011, which have undergone modifications until reaching the classification most used currently, published in the 2018 International Consensus on Musculoskeletal Infection by Parvizi et al.[9] ([Table 1]).
There are various ways of classifying PPIs, with the presentation time being one of the most widely used. One of the first classifications of this type is the one proposed by Coventry[15] in 1975, which was soon modified by Fitzgerald et al.[16] in 1977, who group them into acute, subacute and late ([Table 2]).[14] [15] [16]
For the correct treatment of a case of PPI, it is essential to isolate and identify the etiological agent. The main microorganisms described are gram-positive bacteria, gram-negative bacteria, and fungi in third place.[17] [18]
Given the scarcity of data published in this regard in Chile, the present study becomes necessary in order to know the regional reality in terms of the most prevalent microorganisms, their sensitivity, and the characteristics of patients affected by PPI.
#
Materials and methods
We obtained the complete casuistry of patients who underwent TKA due to severe gonarthrosis in a public hospital in Santiago de Chile. A descriptive and retrospective study of these patients was carried out, including all those who underwent primary total knee arthroplasty between 2001 and 2020, with a minimum follow-up of 1 year.
Until 2018, patients who met the PPI criteria according to the main international guidelines (Tsukayama et al.[12] and MSIS[13]) were identified and included; after 2018, the diagnostic method was guided by the Philadelphia consensus of the same year.
We excluded all patients operated on at other health centers, those with revision prostheses, and those who had incomplete clinical records.
The surgical technique used followed the manufacturer's instructions and the prosthesis model. In addition, surgical protocols and asepsis and antisepsis techniques were used, respecting the quality standards of the hospital, with three doses of cefazolin as the antibiotic surgical protocol (vancomycin in the case of patients allergic to cephalosporins). All interventions were performed with medial parapatellar approach, use of ischemia handle, and without the use of drainage.
Regarding the patients with PPI, the following variables were analyzed:
- Demographics: age, gender, previous illnesses and body mass index (BMI).
- Surgical: surgical time and antibiotic prophylaxis.
- Microbiological: isolated microorganism, and antibiotic susceptibility and resistance.
Each infection was classified according to its temporality between the TKA and the moment of PPI diagnosis, using the classification described by Fitzgerald et al.,[16] and recording the microbiological variables found for each case.
Secondly, we analyzed the antibiotic and/or surgical management that was carried out in the PPI patients and the morbidity and mortality after the treatment.
Finally, a descriptive analysis of the different variables was performed using Microsoft Excel 2020 (Microsoft Corp., Redmond, WA, United States).
The study was approved by the institutional ethics committee.
#
Results
Between 2001 and 2020, a total of 544 TKAs were performed, and 8 patients (1.47%) presented PPIs in their subsequent evolution.
Of those 8 patients (1.47%), 3 were male, and 5, female, with a mean age at the time of installation of the primary prosthesis of 66 (±5.7) years, all with a presurgical diagnosis of severe gonarthrosis.
Among the morbid conditions, the obesity of the patients stands out, with an average BMI of 30.3 (±4.5) kg/m2; all patients had an associated comorbidity (hypertension, smoking, diabetes, or other).
All patients received antibiotic prophylaxis with 1 g of intravenous cefazolin preoperatively and 2 doses postoperatively. The mean operative time was of 114 (±23.3) minutes.
The time elapsed between the primary TKA and reoperation ranged from 12 to 3,324 days, with a median of 411 days. Regarding the presentation, it was acute in 3 (37.5%) patients, subacute in 3 (37.5%) and late in 2 (25%) cases ([Table 3]).
Patient |
Days |
---|---|
Patient 1 |
455 |
Patient 2 |
367 |
Patient 3 |
14 |
Patient 4 |
12 |
Patient 5 |
614 |
Patient 6 |
3,315 |
Patient 7 |
1,125 |
Patient 8 |
43 |
The main reason for consultation was joint pain in 6 cases, while the remaining 2 were joint stiffness. No patient presented with fever, and only 1 (12.5%) presented a fistula.
Regarding the laboratory tests, C-reactive protein (CRP) on admission was elevated in 7/8 patients and the leukocytes were elevated in 3 cases.
In total, 5 (62.5%) of the patients with PPI presented polymicrobial etiology, while the other 3 (37.5%), a single causal bacterial agent was found. The main isolated agent was multidrug-resistant Staphylococcus aureus, which occurred in 75% of the patients. The other causal agents found are described in [Table 4].
SA |
EF |
CNS |
SE |
EC |
AB |
KBL |
SH |
SP |
PAE |
|
---|---|---|---|---|---|---|---|---|---|---|
Patient 1 |
+ |
+ |
- |
- |
- |
- |
- |
- |
- |
- |
Patient 2 |
- |
- |
+ |
+ |
- |
- |
- |
- |
- |
- |
Patient 3 |
+ |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Patient 4 |
+ |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Patient 5 |
+ |
- |
+ |
- |
+ |
+ |
- |
- |
- |
- |
Patient 6 |
+ |
- |
- |
- |
- |
- |
+ |
- |
- |
- |
Patient 7 |
- |
- |
- |
- |
- |
- |
- |
+ |
- |
- |
Patient 8 |
+ |
- |
- |
- |
- |
- |
- |
- |
- |
+ |
Regarding antibiotic sensitivity, we found that all cultures that were positive for S. aureus were sensitive to vancomycin and rifampicin. On the other hand, a high resistance against ciprofloxacin was observed.
The remaining sensitivity rates of other antibiotics are described in [Table 5].
Antibiotic |
Sensitivity: % (sensitive/cultures studied) |
---|---|
Vancomycin |
100% (12/12) |
Rifampicin |
100% (12/12) |
Sulfamethoxazole-trimethoprim |
100% (10/10) |
Linezolid |
100% (9/9) |
Gentamicin |
100% (9/9) |
Ceftaroline |
100% (8/8) |
Clindamycin |
50% (6/12) |
Erythromycin |
45% (5/11) |
Oxacillin |
45% (5/11) |
Ciprofloxacin |
44% (4/9) |
Of the total number of patients, 7 (87.5%) underwent revision prostheses in 2 stages, while the remaining patient (12.5%) underwent removal of the infected prosthesis and 3 surgical knee cleanings, subsequently dying from septic shock secondary to endocarditis.
#
Discussion
Though it can result in serious complications such as PPI, TKA has been increasingly performed. The incidence of PPI in our center was of 1.47%, which is within the percentages described in the literature.[19] [20]
Among the main risk factors for developing a PPI, we find obesity, diabetes mellitus and rheumatoid arthritis, among others.[5] [21] It is noteworthy that most of the patients in the present study had a high BMI, in addition to some of the other risk factors mentioned, which suggests that not only the conditions of the health center are important, but also patient's medical condition.
The follow-up of patients after TKA has not been defined, and it varies according to the guideline or medical center. We can observe, for example, that the Arthroplasty Society of Australia[22] recommends an annual follow-up from the first to the tenth postoperative years and, thereafter, every three to five years. On the other hand, Mending et al.[23] followed up 11,019 TKAs, investigating the temporal peaks of risk of failure, and concluded that the optimal moments of follow-up include 6 and 12 months, then 3, 8, 12, and 17 years, and these last 2 periods are recommended for those with a BMI greater than 40 kg/m2. In the present study, we observed infections with a median of 411 days and great dispersion, ranging from 12 to 3,315 days (9 years); based on what was previously published and according to what we found in the present study, it seems reasonable to us to recommend an annual clinical follow-up after the first postoperative year, continuing up to 10 years after surgery.
Once the diagnosis of PPI is suspected, the choice of the empirical antibiotic regimen should be made considering the main and most likely etiologies. There is great variability within the literature in this regard; Jaén et al.[24] conducted a multicenter study in Spain in which they isolated Staphylococcus epidermidis as the main infectious agent, while Girón-Cornelio[25] in a literature review with a focus on health centers in Peru, found that the main etiology was coagulase-negative Staphylococcus. In the present study, on the other hand, we found multidrug-resistant S. aureus as the main infectious agent, which does not correlate with the previously-described etiologies and shows that there is a high variability regarding the main agent in each center.[24] [25]
The study by Leijtens et al.[26] showed a high sensitivity to the combination of clindamycin and rifampicin, while Gellert et al.[27] showed the treatment with various antibiotic biofilms, including rifampicin, ampicillin and ciprofloxacin, according to the susceptibility. In our local population, we were able to identify multirug-resistant S. aureus as the most prevalent agent, with vancomycin and rifampicin as the ideal antibiotics to eradicate the infection, while we observed high resistance to ciprofloxacin and erythromycin. It should be noted that the antibiotics sulfamethoxazole-trimethoprim, linezolid, and gentamicin presented high sensitivity; however, they were studied in a smaller number of cases. Given this difference that is observed within the different health centers, it seems reasonable to recommend using the international treatment guidelines only as a first approach, but that each center has its own study of etiological agents with regards to the identification of the most frequent pathogens and their antibiotic susceptibilities.
Within the limitations of our study, we can mention both the low number of TKAs and PPIs in the sample, which could exaggerate the rates of the variables measured. On the other hand, we did not perform a comparison of the risk factors for PPI with a control group that did not present infection. This motivates us to propose a new line of research, with a regional and national multicenter study, to describe the incidence, isolated microorganisms, and susceptibility, in order to analyze trends and develop a national management and treatment guide.
Another point to consider is that, although the sample of the present study is kept under strict and closely-monitored follow-up due to their health insurance, it is possible that a patient has made a change of address or city and developed PPI, which could affect the final incidence of PPI. In any case, we estimate that it should not correspond to a relevant factor, since all the patients adhered to the follow-up in our center in the years following their intervention.
As strengths, we highlight the long period covered by the present study (18 years), a standardized intervention by the same team, the diagnosis based on the latest relevant international guidelines, and the analysis of the microbiological variables for each of the PPI cases, also detailing the antibiotic susceptibility study, which could serve as a guide for the different groups when deciding which empirical antibiotic treatment to use in a case of PPI.
#
Conclusion
The incidence of PPI found in the present study was of 1.47%. All patients with PPI presented some preoperative comorbidity. The main microbiological agents identified were multidrug-resistant and susceptible to vancomycin and rifampicin.
#
#
-
Referencias
- 1 Parvizi J, Zmistowski B, Berbari EF. et al. New definition for periprosthetic joint infection: from the Workgroup of the Musculoskeletal Infection Society. Clin Orthop Relat Res 2011; 469 (11) 2992-2994
- 2 Blanco JF, Díaz A, Melchor FR, da Casa C, Pescador D. Risk factors for periprosthetic joint infection after total knee arthroplasty. Arch Orthop Trauma Surg 2020; 140 (02) 239-245 DOI: 10.1007/s00402-019-03304-6.
- 3 Lenz R, Paredes D, Edwards D, Galvez P. 2020 Evaluación económica en salud: costo-utilidad de la incorporación del reemplazo total de rodilla en la cobertura del régimen de Garantías Explícitas en Salud en Chile. [online] Medwave.cl. [Accessed 5 May 2021]. at: https://www.medwave.cl/medios/medwave/Diciembre2020/8086/Anx02_8086.pdf
- 4 Ricciardi BF, Muthukrishnan G, Masters EA, Kaplan N, Daiss JL, Schwarz EM. New developments and future challenges in prevention, diagnosis, and treatment of prosthetic joint infection. J Orthop Res 2020; 38 (07) 1423-1435 DOI: 10.1002/jor.24595.
- 5 Kunutsor SK, Whitehouse MR, Blom AW, Beswick AD. INFORM Team. Patient-Related Risk Factors for Periprosthetic Joint Infection after Total Joint Arthroplasty: A Systematic Review and Meta-Analysis. PLoS One 2016; 11 (03) e0150866 DOI: 10.1371/journal.pone.0150866.
- 6 Premkumar A, Morse K, Levack AE, Bostrom MP, Carli AV. Periprosthetic Joint Infection in Patients with Inflammatory Joint Disease: Prevention and Diagnosis. Curr Rheumatol Rep 2018; 20 (11) 68
- 7 Parvizi J, Shohat N, Gehrke T. Prevention of periprosthetic joint infection: new guidelines. Bone Joint Lett J, 99-b (2017), pp. 3-10
- 8 Henk E, Brian D, Ian S. et al. Can short term (two weeks or less) antibiotic treatment be considered following resection arthroplasty for chronic periprosthetic joint infections (PJIs)? Proceedings of the International Consensus Meeting on Prosthetic Joint Infection. Philadelphia: 2018 . Part II-Hip and Knee: 500–501. Available at: https://icmphilly.com/wpcontent/uploads/2018/11/Hip-and-Knee.pdf
- 9 Parvizi J, Tan TL, Goswami K. et al. The 2018 Definition of Periprosthetic Hip and Knee Infection: An Evidence-Based and Validated Criteria. J Arthroplasty 2018; 33 (05) 1309-1314.e2 DOI: 10.1016/j.arth.2018.02.078.
- 10 Huerfano E, Bautista M, Huerfano M, Bonilla G, Llinas A. Screening for infection before revision hip arthroplasty: a meta‐analysis of likelihood ratios of erythrocyte sedimentation rate and serum C‐reactive protein Levels. J Am Acad Orthop Surg 2017; 25 (12) 809-817
- 11 Lee YS, Koo KH, Kim HJ. et al. Synovial fluid biomarkers for the diagnosis of periprosthetic joint infection: a systematic review and meta‐analysis. J Bone Joint Surg Am 2017; 99 (24) 2077-2084
- 12 Tsukayama DT, Estrada R, Gustilo RB. Infection after total hip arthroplasty. A study of the treatment of one hundred and six infections. J Bone Joint Surg Am 1996; 78 (04) 512-523
- 13 Workgroup Convened by the Musculoskeletal Infection Society. New definition for periprosthetic joint infection. J Arthroplasty 2011; 26 (08) 1136-1138
- 14 Porrino J, Wang A, Moats A, Mulcahy H, Kani K. Prosthetic joint infections: diagnosis, management, and complications of the two-stage replacement arthroplasty. Skeletal Radiol 2020; 49 (06) 847-859 DOI: 10.1007/s00256-020-03389-w.
- 15 Coventry MB. Treatment of infections occurring in total hip surgery. Orthop Clin North Am 1975; 6 (04) 991-1003
- 16 Fitzgerald Jr RH, Nolan DR, Ilstrup DM, Van Scoy RE, Washington II JA, Coventry MB. Deep wound sepsis following total hip arthroplasty. J Bone Joint Surg Am 1977; 59 (07) 847-855
- 17 Lima AL, Oliveira PR, Carvalho VC, Saconi ES, Cabrita HB, Rodrigues MB. Periprosthetic joint infections. Interdiscip Perspect Infect Dis 2013; 2013: 542796 DOI: 10.1155/2013/542796.
- 18 Carvalho VC. Osteomielite por bacilos Gram-negativos: estudo comparativo das características clínico-microbiológicas e fatores de risco com as infecções por Staphylococcus aureus[tese]. São Paulo: : Faculdade de Medicina da Universidade de São Paulo; 2013
- 19 Kapadia BH, Berg RA, Daley JA, Fritz J, Bhave A, Mont MA. Periprosthetic joint infection. Lancet 2016; 387 (10016): 386-394 DOI: 10.1016/s0140-6736(14)61798-0.
- 20 Kurtz SM, Ong KL, Lau E, Bozic KJ, Berry D, Parvizi J. Prosthetic joint infection risk after TKA in the Medicare population. Clin Orthop Relat Res 2010; 468 (01) 52-56 DOI: 10.1007/s11999-009-1013-5.
- 21 Kong L, Cao J, Zhang Y, Ding W, Shen Y. Risk factors for periprosthetic joint infection following primary total hip or knee arthroplasty: a meta-analysis. Int Wound J 2017; 14 (03) 529-536 DOI: 10.1111/iwj.12640.
- 22 Broughton N, Collopy D, Solomon M. Arthroplasty Society of Australia. Arthroplasty Society of Australia position statement on follow-up of joint replacement patients. 2016 https://www.aoa.org.au/docs/default-source/states/arthroplasty-follow-up-guidelines-2016.pdf?sfvrsn = 2 (date last accessed 01 September 2017).
- 23 Meding JB, Ritter MA, Davis KE, Farris A. Meeting increased demand for total knee replacement and follow-up: determining optimal follow-up. Bone Joint J 2013; 95-B (11) 1484-1489
- 24 Jaén F, Sanz-Gallardo MI, Arrazola MP, García de Codes A, de Juanes A, Resines C. Grupo de Trabajo INCLIMECC de la Comunidad de Madrid. Estudio multicéntrico sobre la incidencia de infección en prótesis de rodilla. Rev Esp Cir Ortop Traumatol 2012; 56 (01) 38-45
- 25 Girón-Cornelio MF. Infecciones de prótesis de rodilla. Rev Méd Panacea 2019; ;8(1): 46-54
- 26 Leijtens B, Elbers JBW, Sturm PD, Kullberg BJ, Schreurs BW. Clindamycin-rifampin combination therapy for staphylococcal periprosthetic joint infections: a retrospective observational study. BMC Infect Dis 2017; 17 (01) 321 DOI: 10.1186/s12879-017-2429-2.
- 27 Gellert M, Hardt S, Köder K, Renz N, Perka C, Trampuz A. Biofilm-active antibiotic treatment improves the outcome of knee periprosthetic joint infection: Results from a 6-year prospective cohort study. Int J Antimicrob Agents 2020; 55 (04) 105904 DOI: 10.1016/j.ijantimicag.2020.105904.
Address for correspondence
Publication History
Received: 01 December 2021
Accepted: 17 May 2022
Article published online:
03 October 2022
© 2022. Sociedad Chilena de Ortopedia y Traumatologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
Referencias
- 1 Parvizi J, Zmistowski B, Berbari EF. et al. New definition for periprosthetic joint infection: from the Workgroup of the Musculoskeletal Infection Society. Clin Orthop Relat Res 2011; 469 (11) 2992-2994
- 2 Blanco JF, Díaz A, Melchor FR, da Casa C, Pescador D. Risk factors for periprosthetic joint infection after total knee arthroplasty. Arch Orthop Trauma Surg 2020; 140 (02) 239-245 DOI: 10.1007/s00402-019-03304-6.
- 3 Lenz R, Paredes D, Edwards D, Galvez P. 2020 Evaluación económica en salud: costo-utilidad de la incorporación del reemplazo total de rodilla en la cobertura del régimen de Garantías Explícitas en Salud en Chile. [online] Medwave.cl. [Accessed 5 May 2021]. at: https://www.medwave.cl/medios/medwave/Diciembre2020/8086/Anx02_8086.pdf
- 4 Ricciardi BF, Muthukrishnan G, Masters EA, Kaplan N, Daiss JL, Schwarz EM. New developments and future challenges in prevention, diagnosis, and treatment of prosthetic joint infection. J Orthop Res 2020; 38 (07) 1423-1435 DOI: 10.1002/jor.24595.
- 5 Kunutsor SK, Whitehouse MR, Blom AW, Beswick AD. INFORM Team. Patient-Related Risk Factors for Periprosthetic Joint Infection after Total Joint Arthroplasty: A Systematic Review and Meta-Analysis. PLoS One 2016; 11 (03) e0150866 DOI: 10.1371/journal.pone.0150866.
- 6 Premkumar A, Morse K, Levack AE, Bostrom MP, Carli AV. Periprosthetic Joint Infection in Patients with Inflammatory Joint Disease: Prevention and Diagnosis. Curr Rheumatol Rep 2018; 20 (11) 68
- 7 Parvizi J, Shohat N, Gehrke T. Prevention of periprosthetic joint infection: new guidelines. Bone Joint Lett J, 99-b (2017), pp. 3-10
- 8 Henk E, Brian D, Ian S. et al. Can short term (two weeks or less) antibiotic treatment be considered following resection arthroplasty for chronic periprosthetic joint infections (PJIs)? Proceedings of the International Consensus Meeting on Prosthetic Joint Infection. Philadelphia: 2018 . Part II-Hip and Knee: 500–501. Available at: https://icmphilly.com/wpcontent/uploads/2018/11/Hip-and-Knee.pdf
- 9 Parvizi J, Tan TL, Goswami K. et al. The 2018 Definition of Periprosthetic Hip and Knee Infection: An Evidence-Based and Validated Criteria. J Arthroplasty 2018; 33 (05) 1309-1314.e2 DOI: 10.1016/j.arth.2018.02.078.
- 10 Huerfano E, Bautista M, Huerfano M, Bonilla G, Llinas A. Screening for infection before revision hip arthroplasty: a meta‐analysis of likelihood ratios of erythrocyte sedimentation rate and serum C‐reactive protein Levels. J Am Acad Orthop Surg 2017; 25 (12) 809-817
- 11 Lee YS, Koo KH, Kim HJ. et al. Synovial fluid biomarkers for the diagnosis of periprosthetic joint infection: a systematic review and meta‐analysis. J Bone Joint Surg Am 2017; 99 (24) 2077-2084
- 12 Tsukayama DT, Estrada R, Gustilo RB. Infection after total hip arthroplasty. A study of the treatment of one hundred and six infections. J Bone Joint Surg Am 1996; 78 (04) 512-523
- 13 Workgroup Convened by the Musculoskeletal Infection Society. New definition for periprosthetic joint infection. J Arthroplasty 2011; 26 (08) 1136-1138
- 14 Porrino J, Wang A, Moats A, Mulcahy H, Kani K. Prosthetic joint infections: diagnosis, management, and complications of the two-stage replacement arthroplasty. Skeletal Radiol 2020; 49 (06) 847-859 DOI: 10.1007/s00256-020-03389-w.
- 15 Coventry MB. Treatment of infections occurring in total hip surgery. Orthop Clin North Am 1975; 6 (04) 991-1003
- 16 Fitzgerald Jr RH, Nolan DR, Ilstrup DM, Van Scoy RE, Washington II JA, Coventry MB. Deep wound sepsis following total hip arthroplasty. J Bone Joint Surg Am 1977; 59 (07) 847-855
- 17 Lima AL, Oliveira PR, Carvalho VC, Saconi ES, Cabrita HB, Rodrigues MB. Periprosthetic joint infections. Interdiscip Perspect Infect Dis 2013; 2013: 542796 DOI: 10.1155/2013/542796.
- 18 Carvalho VC. Osteomielite por bacilos Gram-negativos: estudo comparativo das características clínico-microbiológicas e fatores de risco com as infecções por Staphylococcus aureus[tese]. São Paulo: : Faculdade de Medicina da Universidade de São Paulo; 2013
- 19 Kapadia BH, Berg RA, Daley JA, Fritz J, Bhave A, Mont MA. Periprosthetic joint infection. Lancet 2016; 387 (10016): 386-394 DOI: 10.1016/s0140-6736(14)61798-0.
- 20 Kurtz SM, Ong KL, Lau E, Bozic KJ, Berry D, Parvizi J. Prosthetic joint infection risk after TKA in the Medicare population. Clin Orthop Relat Res 2010; 468 (01) 52-56 DOI: 10.1007/s11999-009-1013-5.
- 21 Kong L, Cao J, Zhang Y, Ding W, Shen Y. Risk factors for periprosthetic joint infection following primary total hip or knee arthroplasty: a meta-analysis. Int Wound J 2017; 14 (03) 529-536 DOI: 10.1111/iwj.12640.
- 22 Broughton N, Collopy D, Solomon M. Arthroplasty Society of Australia. Arthroplasty Society of Australia position statement on follow-up of joint replacement patients. 2016 https://www.aoa.org.au/docs/default-source/states/arthroplasty-follow-up-guidelines-2016.pdf?sfvrsn = 2 (date last accessed 01 September 2017).
- 23 Meding JB, Ritter MA, Davis KE, Farris A. Meeting increased demand for total knee replacement and follow-up: determining optimal follow-up. Bone Joint J 2013; 95-B (11) 1484-1489
- 24 Jaén F, Sanz-Gallardo MI, Arrazola MP, García de Codes A, de Juanes A, Resines C. Grupo de Trabajo INCLIMECC de la Comunidad de Madrid. Estudio multicéntrico sobre la incidencia de infección en prótesis de rodilla. Rev Esp Cir Ortop Traumatol 2012; 56 (01) 38-45
- 25 Girón-Cornelio MF. Infecciones de prótesis de rodilla. Rev Méd Panacea 2019; ;8(1): 46-54
- 26 Leijtens B, Elbers JBW, Sturm PD, Kullberg BJ, Schreurs BW. Clindamycin-rifampin combination therapy for staphylococcal periprosthetic joint infections: a retrospective observational study. BMC Infect Dis 2017; 17 (01) 321 DOI: 10.1186/s12879-017-2429-2.
- 27 Gellert M, Hardt S, Köder K, Renz N, Perka C, Trampuz A. Biofilm-active antibiotic treatment improves the outcome of knee periprosthetic joint infection: Results from a 6-year prospective cohort study. Int J Antimicrob Agents 2020; 55 (04) 105904 DOI: 10.1016/j.ijantimicag.2020.105904.